Related Experiment Video
Updated: Jan 22, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis
Fyona Okundia1, Muna Shakhashiro1, Stephen K. Tyring1,2
1Center for Clinical Studies, Houston, TX, USA.
Biologics have emerged in recent years as relatively safe and effective options for managing plaque psoriasis, however, a subset of patients remain reluctant to initiate biologic therapy. Icotrokinra is a novel, first-in-class oral peptide that targets the interleukin-23 receptor and has demonstrated a favorable safety and efficacy profile comparable to that of injectable biologics in individuals aged 12 years and older. This review summarizes the clinical trial data regarding the safety and efficacy of icotrokinra.
Biologics have emerged in recent years as relatively safe and effective options for managing plaque psoriasis, however, a subset of patients remain reluctant to initiate biologic therapy. Icotrokinra is a novel, first-in-class oral peptide that targets the interleukin-23 receptor and has demonstrated a favorable safety and efficacy profile comparable to that of injectable biologics in individuals aged 12 years and older. This review summarizes the clinical trial data regarding the safety and efficacy of icotrokinra.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Oral Cavity
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Internal Receptors

